Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid Abstract #2891

Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.
Aim(s): To evaluate SREs and their outcomes in NEN pts with BM, treated with zoledronic acid (ZA).
Materials and methods: The diagnosis of NEN BM was based on molecular and/or cross-sectional imaging. Eligible pts received at least 2 cycles of ZA and time to first SRE was defined as presence of a pathological fracture, and/or need for spinal surgery and/or external beam radiotherapy (EBR) for pain control or spinal cord compression. Time to SRE and overall survival (OS) were estimated using the Kaplan-Meier method.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Eleni Armeni

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result